AU6501390A - Method for transporting compositions across the blood brain barrier - Google Patents

Method for transporting compositions across the blood brain barrier

Info

Publication number
AU6501390A
AU6501390A AU65013/90A AU6501390A AU6501390A AU 6501390 A AU6501390 A AU 6501390A AU 65013/90 A AU65013/90 A AU 65013/90A AU 6501390 A AU6501390 A AU 6501390A AU 6501390 A AU6501390 A AU 6501390A
Authority
AU
Australia
Prior art keywords
brain barrier
blood brain
transporting compositions
transporting
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65013/90A
Inventor
Franklin D. Collins
Robert C. Thompson
Michael J. Yarus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Boulder Inc
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergen Inc filed Critical Synergen Inc
Publication of AU6501390A publication Critical patent/AU6501390A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A63—SPORTS; GAMES; AMUSEMENTS
    • A63F—CARD, BOARD, OR ROULETTE GAMES; INDOOR GAMES USING SMALL MOVING PLAYING BODIES; VIDEO GAMES; GAMES NOT OTHERWISE PROVIDED FOR
    • A63F3/00—Board games; Raffle games
    • A63F3/06—Lottos or bingo games; Systems, apparatus or devices for checking such games
    • A63F3/065—Tickets or accessories for use therewith
    • A63F3/0685—Tickets or accessories for use therewith having a message becoming legible after a chemical reaction or physical action has taken place, e.g. applying pressure, heat treatment, spraying with a substance, breaking microcapsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Multimedia (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU65013/90A 1989-09-21 1990-09-21 Method for transporting compositions across the blood brain barrier Abandoned AU6501390A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41031989A 1989-09-21 1989-09-21
US410319 1989-09-21

Publications (1)

Publication Number Publication Date
AU6501390A true AU6501390A (en) 1991-04-18

Family

ID=23624209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65013/90A Abandoned AU6501390A (en) 1989-09-21 1990-09-21 Method for transporting compositions across the blood brain barrier

Country Status (3)

Country Link
AU (1) AU6501390A (en)
CA (1) CA2025907A1 (en)
WO (1) WO1991004014A1 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948384A (en) * 1990-09-14 1999-09-07 Syngenix Limited Particulate agents
GB9020075D0 (en) 1990-09-14 1990-10-24 Filler Aaron G Contrast agents for magnetic resonance imaging of axonal transport
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US6919067B2 (en) 1991-09-13 2005-07-19 Syngenix Limited Compositions comprising a tissue glue and therapeutic agents
CA2141216A1 (en) * 1992-07-27 1994-02-03 Michael J. Micklus Targeting of liposomes to the blood-brain barrier
DE4303646A1 (en) * 1993-02-09 1994-08-11 Basf Ag The use of thrombin inhibitors to combat neurodegenerative diseases
AU7564194A (en) * 1993-09-10 1995-03-27 University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
DE69529054T2 (en) * 1994-02-28 2003-08-21 Nanopharm Ag SYSTEM FOR TARGETED ACTIVE SUBSTANCE, METHOD FOR THE PRODUCTION AND USE THEREOF
ES2312177T3 (en) 1996-05-22 2009-02-16 Viventia Biotech Inc. FRAGMENTS OF UNION TO ANTIGENS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES THAT CODIFY FRAGMENTS AND THE USE OF THE SAME FOR THE PROFILAXIS AND CANCER DETECTION.
JP2001508648A (en) 1996-11-06 2001-07-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Tumor necrosis factor receptor releasing enzyme, composition containing the enzyme, and method of using the same
US7115722B1 (en) 1997-05-22 2006-10-03 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
US8251986B2 (en) 2000-08-17 2012-08-28 Angiodynamics, Inc. Method of destroying tissue cells by eletroporation
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PA8536201A1 (en) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IL158623A0 (en) 2001-04-30 2004-05-12 Symbiontics Inc Subcellular targeting of therapeutic proteins
US6994706B2 (en) 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2003032727A1 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
KR101086533B1 (en) 2002-05-24 2011-11-23 쉐링 코포레이션 Neutralizing human anti-IGFR antibody, a method for producing it and a composition comprising it
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
PT2274978E (en) 2003-09-12 2015-07-09 Ipsen Biopharmaceuticals Inc Methods for treatment of insulin-like growth factor-i(igf-i) deficiency
ATE514783T1 (en) 2003-11-12 2011-07-15 Schering Corp PLASMID SYSTEM FOR EXPRESSING MULTIPLE GENES
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
US20050244400A1 (en) 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
JP2008521907A (en) 2004-12-03 2008-06-26 シェーリング コーポレイション Biomarkers for preselecting patients for anti-IGF1R treatment
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
PT2371855E (en) 2005-08-05 2015-11-03 Araim Pharmaceuticals Inc Tissue protective peptides and uses thereof
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
US8895303B2 (en) 2006-11-13 2014-11-25 Charite-Universitatsmedizin Berlin Method of cell culture and method of treatment comprising a vEPO protein variant
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CA2721568A1 (en) * 2008-04-17 2009-10-22 Banyan Biomarkers, Inc. An antibody bound synthetic vesicle containing active agent molecules
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US8992517B2 (en) 2008-04-29 2015-03-31 Virginia Tech Intellectual Properties Inc. Irreversible electroporation to treat aberrant cell masses
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US9283051B2 (en) 2008-04-29 2016-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US9598691B2 (en) 2008-04-29 2017-03-21 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US9198733B2 (en) 2008-04-29 2015-12-01 Virginia Tech Intellectual Properties, Inc. Treatment planning for electroporation-based therapies
HUE034850T2 (en) 2008-05-07 2018-03-28 Biomarin Pharm Inc Lysosomal targeting peptides and uses thereof
EP2342356A4 (en) 2008-09-29 2012-11-21 Univ Ben Gurion Amyloid beta-peptides and methods of use thereof
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
WO2010138919A2 (en) 2009-05-28 2010-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
EP2509953B1 (en) 2009-12-11 2016-03-30 Genecode AS Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
US9700368B2 (en) 2010-10-13 2017-07-11 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
EP2637652A2 (en) 2010-11-10 2013-09-18 Katholieke Universiteit Leuven Osteoclast activity
WO2012088149A2 (en) 2010-12-20 2012-06-28 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
JP6038122B2 (en) 2011-04-21 2016-12-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Functional magnetic nanoparticles and their use in image processing of amyloid deposits and neurofibrillary tangles
MX2014007664A (en) 2011-12-22 2015-05-11 Nuvo Res Gmbh Liposomal chlorite or chlorate compositions.
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
CA3052449C (en) 2013-03-11 2021-10-19 Jan Remmereit Lipid compositions comprising 5, 11, 14-eicosatrienoic acid and conjugated linoleic acids
EP3088518A4 (en) 2013-12-25 2017-09-20 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
WO2015175570A1 (en) 2014-05-12 2015-11-19 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US10694972B2 (en) 2014-12-15 2020-06-30 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
CA3033694C (en) 2016-09-15 2023-06-27 Universitat Stuttgart Antigen binding protein against her3
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP3411400B1 (en) 2017-04-03 2021-09-22 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
CN110997693A (en) 2017-06-07 2020-04-10 阿德克斯公司 Tau aggregation inhibitors
CN111201241A (en) 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 Treatment of inflammatory diseases with inhibitors of C5a activity
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
CN113056286A (en) 2018-09-10 2021-06-29 冷泉港实验室 Methods for treating pancreatitis
KR20210137157A (en) 2019-03-11 2021-11-17 인플라알엑스 게엠베하 Fused piperidinyl bicyclic compounds and related compounds as receptor modulators of C5a
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
US20230158060A1 (en) 2020-03-27 2023-05-25 Inflarx Gmbh Inhibitors of C5a for the Treatment of Corona Virus Infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
FR2534487B1 (en) * 1982-10-15 1988-06-10 Dior Christian Parfums METHOD FOR THE HOMOGENEIZATION OF HYDRATED LIPIDAL LAMELLAR PHASE DISPERSIONS, AND SUSPENSIONS OBTAINED THEREBY
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH01149718A (en) * 1987-12-07 1989-06-12 Yoshikatsu Eto Liposome preparation easily passing through blood-brain barrier

Also Published As

Publication number Publication date
CA2025907A1 (en) 1991-03-22
WO1991004014A1 (en) 1991-04-04

Similar Documents

Publication Publication Date Title
AU6501390A (en) Method for transporting compositions across the blood brain barrier
AU6714890A (en) Method for disinfecting medical materials
AU6967991A (en) Catheter atherotome
AU6152590A (en) Valvulotome catheter
AU613269B2 (en) Medical container replacing method
HU9301404D0 (en) Method for preparing medical preparatives
EP0626413A3 (en) Method for the preparation of diorganopolysiloxanes.
AU4046189A (en) Sterilising methods
AU1712192A (en) Method for obtaining blood
AU627075B2 (en) Anthelmintics
AU584008B2 (en) Method for the preparing epichlorohydrins
AU6765190A (en) Anthelmintics
AU5583190A (en) Compounds
GR900100270A (en) Preparation method for 2-substituted n n-bitrimethoxybenzol-piperazines
AU2501288A (en) Sialocylglycerolipids and method for preparing the same
AU6739390A (en) Method of inhibiting the transport of l-glutamate
GR900100167A (en) Method for preparining sulfo-triazolo-diazepines sulfonylic derivatives
AU6320390A (en) Anthelmintics
AU6708690A (en) Underbody for fast sailing-boats
PH29991A (en) Method for the preparation of 9-amino-1,2,3,4-tetrahydro-acridine
EP0474016A3 (en) Method for the preparation of 2,3-dihydro-benzofuranes
EP0434376A3 (en) Ivermectin derivative compounds and process for preparing the same
IL96282A0 (en) Method for the preparation of 5-chlorcarbonyl-5h-dibenz-/b,f/-azepin
GB8921635D0 (en) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
EP0641764A3 (en) Process for the preparation of hydroxyalkylaminonitrobenzene derivatives.